Previous close | 0.4000 |
Open | 0.4000 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 7.50 |
Expiry date | 2024-07-19 |
Day's range | 0.4000 - 0.4000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Key Insights Institutions' substantial holdings in Lyell Immunopharma implies that they have significant influence over...
Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, CA, April 5-10. One oral and two poster presentations will highlight data fro